|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
04.11.25 - 13:06
|
Zoetis Announces Third Quarter 2025 Results (Business Wire)
|
|
|
Reports Revenue of $2.4 Billion, Growing 1%, and Net Income of $721 Million, or $1.63 per Diluted Share, Increasing 6% and 9%, Respectively, on a Reported Basis for Third Quarter 2025
Delivers 4% Organic Operational Growth in Revenue and 9% Organic Operational Growth in Adjusted Net Income for Third Quarter 2025
Reports Adjusted Net Income of $754 Million, or Adjusted Diluted EPS of $1.70, for Third Quarter 2025
Revises Full Year 2025 Revenue Guidance to $9.400 - $9.475 Billion with Organic Operational Revenue Growth of 5.5% to 6.5% Based on Broader Macro Trends and the Operational Environment
Narrows Full Year 2025 Guidance for Organic Operational Growth in Adjusted Net Income to 5.5% to 7.0% to Reflect Continued Disciplined Execution
Maintains Guidance for Diluted EPS on an Adjusted Basis of $6.30 to $6.40
PARSIPPANY, N.J.--(BUSINESS WIRE)--$ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the third quarter of 2025.
The company reported revenue of $2.4 billion for the t...
|
|
|
03.11.25 - 22:18
|
Zoetis Announces Retirement of Rob Polzer at the End of 2025 and the Appointment of Kevin Esch as President of Research & Development for World Leader in Animal Health Beginning in 2026 (Business Wire)
|
|
|
Dr. Rob Polzer to Retire at the End of the Year After 10-Year Distinguished Career of Advancing Veterinary Medicine and InnovationPARSIPPANY, N.J.--(BUSINESS WIRE)--$ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS) today announced that following a 10-year distinguished career dedicated to advancing veterinary medicine and innovation, Rob Polzer, Ph.D., Executive Vice President and President, Research and Development, has made the personal decision to retire at the end of 2025. After a planful succession process, Zoetis has appointed Kevin Esch, D.V.M, M.P.H., Ph.D., Dipl. ACVP (anatomic) to succeed Dr. Polzer in this role, effective January 1, 2026.
Dr. Esch currently serves as Senior Vice President of Global Therapeutics at Zoetis and joined Zoetis in 2014, after a more than 10-year career as a practicing veterinarian and practice owner. He will become a member of the Zoetis executive team and report to Chief Executive Officer Kristin Peck.
Dr. Polzer will remain in his role until the end of the year and retir...
|
|
|
|
|
|
|
29.10.25 - 23:25
|
XETR: DIVIDEND/INTEREST INFORMATION - 31.10.2025 - US98978V1035 (XETRA)
|
|
|
Das Instrument ZOE US98978V1035 ZOETIS INC. CL.A DL -,01 EQUITY wird cum Dividende/Zinsen gehandelt am 30.10.2025 und ex Dividende/Zinsen am 31.10.2025
The instrument ZOE US98978V1035 ZOETIS INC. CL.A DL -,01 EQUITY has its pre-dividend/interest day on 30.10.2025 and its ex-dividend/interest day on 31.10.2025...
|
|
|
|
|
28.10.25 - 13:36
|
Zoetis Appoints Stephanie Tilenius to its Board of Directors (Business Wire)
|
|
|
Health entrepreneur brings her digital and artificial intelligence (AI) experience to Zoetis BoardPARSIPPANY, N.J.--(BUSINESS WIRE)--$ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS) today announced the appointment of Stephanie Tilenius to its Board of Directors, effective as of December 1, 2025. Ms. Tilenius brings extensive experience in technology-forward, digital health organizations to the Zoetis Board.
Ms. Tilenius is a serial entrepreneur and has founded several healthcare companies, including most recently a stealth company in the longevity AI space. Previously, she founded Vida Health, Inc., a leading B2B chronic care platform focusing on diabetes and obesity, and scaled it nationally for Fortune 500 companies, large payers and healthcare providers. There, she served as CEO from 2014 to 2023.
“We are thrilled to welcome Stephanie Tilenius to the Zoetis Board of Directors,” said Kristin Peck, Chief Executive Officer of Zoetis. “Her strategic thinking and expertise in digital health, AI and technol...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
